期刊文献+
共找到390篇文章
< 1 2 20 >
每页显示 20 50 100
Temozolomide resistance in high grade gliomas
1
作者 卫翔宇 XIE Chao-ran +2 位作者 YOU Chao-guo CHEN Zheng 郑学胜 《上海交通大学学报(医学版)》 CAS CSCD 北大核心 2018年第1期117-124,共8页
High grade gliomas are always the research focus in the field of neurosurgery due to their poor prognosis despite the current standard therapeutic regimen of surgical resection followed by radiation therapy and chemot... High grade gliomas are always the research focus in the field of neurosurgery due to their poor prognosis despite the current standard therapeutic regimen of surgical resection followed by radiation therapy and chemotherapy. Alkylating agent temozolomide has been established as the standard chemotherapy while its resistance inevitable during treatment. This phenomenon seriously influences the prognosis of patients suffering from high grade gliomas. This review aims to elucidate temozolomide chemoresistance mechanisms through three chapters including O^6-methylguanine-DNA methyltransferase(MGMT) methylation, mismatch repair mutation and epigenetic regulation consisting of p21, chromatin and histone, Y-box binding protein-1 and micro RNAs. 展开更多
关键词 high grade glioma TEMOZOLOMIDE RESISTANCE O6-methylguanine-DNA methyltransferase mismatch repair
下载PDF
Abnormal expressions of proliferating cell nuclear antigen and P27 protein in brain glioma
2
作者 Yong feng Hu Wei Shi +3 位作者 Chong xiao Liu Jian jun Sun Rui zhi Wang Zhen yu Guo 《Neural Regeneration Research》 SCIE CAS CSCD 2007年第10期591-594,共4页
Both proliferating cell nuclear antigen and P27 protein are important factors to regulate cell cycle. While, the combination of them can provide exactly objective markers to evaluate prognosis of patients with brain g... Both proliferating cell nuclear antigen and P27 protein are important factors to regulate cell cycle. While, the combination of them can provide exactly objective markers to evaluate prognosis of patients with brain glioma needs to be further studied based on pathological level. OBJECTIVE: To observe the expressions of proliferating cell nuclear antigen and P27 protein in both injured and normal brain glioma tissues and analyze the effect of them on onset and development of brain glioma. DESIGN: Case contrast observation. SETTING: Department of Neurosurgery, the Second Affiliated Hospital of Xi'an Jiaotong University. PARTICIPANTS: A total of 63 patients with brain glioma were selected from Department of Neurosurgery, the Second Affiliated Hospital of Xi'an Jiaotong University from July 1996 to June 2000. There were 38 males and 25 females and their ages ranged from 23 to 71 years. Based on pathological classification and grading standards of brain glioma, patients were divided into grade I - II (n=30) and grade III- IV (n = 33). All cases received one operation but no radiotherapy and chemiotherapy before operation. Sample tissues were collected from tumor parenchyma. Non-neoplastic brain tissues were collected from another 12 non-tumor subjects who received craniocerebral trauma infra-decompression and regarded as the control group. There were l0 males and 2 females and their ages ranged from 16 to 54 years. The experiment had got confirmed consent from local ethic committee and the collection was provided confirmed consent from patients and their relatives. All samples were restained with HE staining so as to diagnose as the brain glioma. While, all patients with brain glioma received radiotherapy after operation and their survival periods were followed up. METHODS: Primary lesion wax of brain glioma was cut into serial sections and stained with S-P immunohistochemical staining. Brown substance which was observed in tumor nucleus was regarded as the positive expressions of both proliferating cell nuclear antigen and P27 protein. Automatic imaging analytic system was used to quantitatively analyze staining results of tumor. MAIN OUTCOME MEASURES: To compare the expressions of proliferating cell nuclear antigen and P27 protein in brain glioma tissues and non-tumor brain tissues and investigate the effect of various sexes, ages, survival periods and severities on the expressions of them in brain tissues. RESULTS: There was no significant difference of sexes and ages in the expressions of proliferating cell nuclear antigen and P27 protein (P 〉 0.05); however, the expressions of proliferating cell nuclear antigen and P27 protein were milder in non-tumor brain tissues than those in the brain glioma tissues (P 〈 0.05). Expression of proliferating cell nuclear antigen in brain tissue of grade III- IV severity was stronger than that of grade I - II severity, and the expression in ≥ 5-year survival periods were also stronger than that in 〈 5-year survival periods (P 〈 0.05). In addition, expression of P27 protein in brain tissue of grade III- IV severity was stronger than that of grade I - II severity, and the expression in ≥ 5-year survival periods were also stronger than that in 〈 5-year survival periods (P 〈 0.05). CONCLUSION: Abnormal expressions of proliferating cell nuclear antigen and P27 protein in human brain glioma are closely related to onset, development and prognosis of tumor. 展开更多
关键词 brain glioma proliferating cell nuclear antigen P27 protein pathological grade PROGNOSIS
下载PDF
Neuro-oncogenesis and the adult human sub-ventricular zone in high grade glioma
3
作者 Sara G.M.Piccirillo 《Neuroimmunology and Neuroinflammation》 2016年第1期20-26,共7页
The last fifteen years have seen the application of the cancer stem cell hypothesis to tumors of the central nervous system,in particular to high grade glioma(HGG),the most aggressive and common brain cancer in adults... The last fifteen years have seen the application of the cancer stem cell hypothesis to tumors of the central nervous system,in particular to high grade glioma(HGG),the most aggressive and common brain cancer in adults.Seminal studies have shown that cancer stem cells(alternatively named tumor-initiating cells)are capable of self-renew and multipotency,similar to their normal counterpart.More importantly they give rise to tumors that closely mimic the phenotype and genotype of human HGG.The identification of neurogenic niches in adult rodent and human brain has further reinforced the hypothesis that HGG might derive from the malignant transformation occurring in these areas,especially in the sub-ventricular zone(SVZ),the largest and most well characterised stem cell niche.Following from evidence of animal model studies supporting this hypothesis,recently we investigated the role of the SVZ in neuro-oncogenesis using tissue material derived from HGG patients.We also described response to conventional chemo-therapies of cancer stem cells isolated from the SVZ and the tumor mass(T)of the same patients and reconstructed tumor evolution.In this review,such findings will be discussed in the context of the current literature on the biology of the SVZ in the normal and disease brain. 展开更多
关键词 high grade glioma tumor-initiating cells sub-ventricular zone tumor development
原文传递
Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches 被引量:19
4
作者 Frederic Dhermain 《Chinese Journal of Cancer》 SCIE CAS CSCD 2014年第1期16-24,共9页
The current standards in radiotherapy of high-grade gliomas(HGG) are based on anatomic imaging techniques, usually computed tomography(CT) scanning and magnetic resonance imaging(MRI). The guidelines vary depending on... The current standards in radiotherapy of high-grade gliomas(HGG) are based on anatomic imaging techniques, usually computed tomography(CT) scanning and magnetic resonance imaging(MRI). The guidelines vary depending on whether the HGG is a histological grade 3 anaplastic glioma(AG) or a grade 4 glioblastoma multiforme(GBM). For AG, T2-weighted MRI sequences plus the region of contrast enhancement in T1 are considered for the delineation of the gross tumor volume(GTV), and an isotropic expansion of 15 to 20 mm is recommended for the clinical target volume(CTV). For GBM, the Radiation Therapy Oncology Group favors a two-step technique, with an initial phase(CTV1) including any T2 hyperintensity area(edema) plus a 20 mm margin treated with up to 46 Gy in 23 fractions, followed by a reduction in CTV2 to the contrast enhancement region in T1 with an additional 25 mm margin. The European Organisation of Research and Treatment of Cancer recommends a single-phase technique with a unique GTV, which comprises the T1 contrast enhancement region plus a margin of 20 to 30 mm. A total dose of 60 Gy in 30 fractions is usually delivered for GBM, and a dose of 59.4 Gy in 33 fractions is typically given for AG. As more than 85% of HGGs recur in field, dose-escalation studies have shown that 70 to 75 Gy can be delivered in 6 weeks with relevant toxicities developing in < 10% of the patients. However, the only randomized dose-escalation trial, in which the boost dose was guided by conventional MRI, did not show any survival advantage of this treatment over the reference arm. HGGs are amongst the most infiltrative and heterogeneous tumors, and it was hypothesized that the most highly aggressive areas were missed; thus, better visualization of these high-risk regions for radiation boost could decrease the recurrence rate. Innovations in imaging and linear accelerators(LINAC) could help deliver the right doses of radiation to the right subvolumes according to the dose-painting concept. Advanced imaging techniques provide functional information on cellular density(diffusion MRI), angiogenesis(perfusion MRI), metabolic activity and cellular proliferation [positron emission tomography(PET) and magnetic resonance spectroscopy(MRS)]. All of these non-invasive techniques demonstrated good association between the images and histology, with up to 40% of HGGs functionally presenting a high activity within the non- contrast-enhanced areas in T1. New LINAC technologies, such as intensity-modulated and stereotactic radiotherapy, help to deliver a simultaneous integrated boost(SIB) > 60 Gy. Trials delivering a SIB into a biological GTV showed the feasibility of this treatment, but the final results, in terms of clinical benefits for HGG patients, are still pending. Many issues have been identified: the variety of MRI and PET machines(and amino-acid tracers), the heterogeneity of the protocols used for image acquisition and post-treatment, the geometric distortion and the unreliable algorithms for co-registration of brain anatomy with functional maps, and the semi-quiescent but highly invasive HGG cells. These issues could be solved by the homogenization of the protocols and software applications, the simultaneous acquisition of anatomic and functional images(PET-MRI machines), the combination of complementary imaging tools(perfusion and diffusion MRI), and the concomitant addition of some ad hoc targeted drugs against angiogenesis and invasiveness to chemoradiotherapy. The integration of these hybrid data will construct new synthetic metrics for fully individualized treatments. 展开更多
关键词 成像技术 放射治疗 胶质瘤 标准 创新 放疗 计算机断层扫描 电子直线加速器
下载PDF
High-grade gliomas: reality and hopes 被引量:6
5
作者 René-Olivier Mirimanoff 《Chinese Journal of Cancer》 SCIE CAS CSCD 2014年第1期1-3,共3页
In this issue of the Chinese Journal of Cancer, European experts review current standards, trends, and future prospects in the difficult domain of high-grade glioma. In all fields covered by the different authors, the... In this issue of the Chinese Journal of Cancer, European experts review current standards, trends, and future prospects in the difficult domain of high-grade glioma. In all fields covered by the different authors, the progress has been impressive. For example, discoveries at the molecular level have already impacted imaging, surgery, radiotherapy, and systemic therapies, and they are expected to play an increasing role in the management of these cancers. The European Organization for Research and Treatment of Cancer(EORTC) has pioneered new treatment strategies and contributed to new standards. The articles in this issue will cover basic molecular biological principles applicable today, novel surgical approaches, innovations in radiotherapy planning and delivery, evidence-based standards for radiotherapy alone or combined with chemotherapy, current standards and novel approaches for systemic treatments, and the important but often neglected field of health-related quality of life. Despite the advances described in these articles, the overall prognosis of high-grade glioma, especially glioblastoma, remains poor, and more research is needed to address this problem. 展开更多
关键词 胶质瘤 全身治疗 分子水平 手术方法 生物学原理 发展趋势 放射治疗 标准
下载PDF
Molecular biology of high-grade gliomas: what should the clinician know? 被引量:7
6
作者 Silvia Hofer Elisabeth Rushing +1 位作者 Matthias Preusser Christine Marosi 《Chinese Journal of Cancer》 SCIE CAS CSCD 2014年第1期4-7,共4页
The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct mol... The current World Health Organization classification system of primary brain tumors is solely based on morphologic criteria. However, there is accumulating evidence that tumors with similar histology have distinct molecular signatures that significantly impact treatment response and survival. Recent practice-changing clinical trials have defined a role for routine assessment of O-6-methylguanine-DNA methyltransferase(MGMT) promoter methylation in glioblastoma patients, especially in the elderly, and 1p and 19q codeletions in patients with anaplastic glial tumors. Recently discovered molecular alterations including mutations in IDH-1/2, epidermal growth factor receptor(EGFR), and BRAF also have the potential to become targets for future drug development. This article aims to summarize current knowledge on the molecular biology of high-grade gliomas relevant to daily practice. 展开更多
关键词 分子生物学 临床试验 胶质瘤 DNA甲基转移酶 表皮生长因子受体 世界卫生组织 医师 甲基鸟嘌呤
下载PDF
Magnetic Resonance Perfusion Imaging in the Diagnosis of High-Grade Glioma Progression and Treatment-Related Changes: A Systematic Review 被引量:1
7
作者 John Dongas Adon Toru Asahina +1 位作者 Stephen Bacchi Sandy Patel 《Open Journal of Modern Neurosurgery》 2018年第3期282-305,共24页
In patients with high grade gliomas (HGGs), progression after treatment can be difficult to diagnose due to treatment-related effects, which overlap in appearance with tumour progression on conventional magnetic reson... In patients with high grade gliomas (HGGs), progression after treatment can be difficult to diagnose due to treatment-related effects, which overlap in appearance with tumour progression on conventional magnetic resonance imaging (MRI) sequences. Specialised imaging methods have been studied for this purpose, though most institutions currently use histopathology or clinicoradiological follow-up for diagnosis. This publication aims to review the evidence for perfusion MRI techniques. The databases of Pubmed, MEDLINE, EMBASE and Scopus were searched using combinations of the subject headings high grade glioma and MRI perfusion. 41 articles fulfilled the inclusion criteria. Dynamic Susceptibility Contrast (DSC) MRI was the most extensively studied, with several studies achieving high sensitivities and specificities. Other techniques exhibiting potential include Dynamic Contrast Enhanced (DCE) MRI, Arterial Spin Labelling (ASL). However, these techniques are not widely used or available for clinical practice. Composite measures combining results from multiple techniques tended to achieve higher accuracies. Some publications compared processing software used or looked at machine learning with relative success. An issue common to the literature is the lack of standardisation in the reference standard and acquisition/processing methods. Furthermore, many had small sample sizes, and further consideration needs to be given with regards to timing of imaging, and treatment regimens received in such studies. 展开更多
关键词 Magnetic RESONANCE Imaging PERFUSION high grade glioma PROGRESSION PSEUDO PROGRESSION
下载PDF
Adaptability of language-related brain network in a low-grade glioma patient
8
作者 Olivera Sveljo Katarina Koprivsek Milos Lucic 《Neural Regeneration Research》 SCIE CAS CSCD 2011年第30期2372-2375,共4页
Because functional magnetic resonance imaging can be used for dynamic observation of functional cortical changes after brain injuries, we followed up functional magnetic resonance imaging manifestations of a language-... Because functional magnetic resonance imaging can be used for dynamic observation of functional cortical changes after brain injuries, we followed up functional magnetic resonance imaging manifestations of a language-related brain network in a low-grade glioma patient. Disease progression and therapy during a 3-year period were followed up at different time points: before and after reoperation, after radiation therapy, and 1 year after irradiation. During the whole 3-year follow-up period, the patient exhibited no neurological deficits while functional magnetic resonance imaging revealed different topologies of the language-related brain network. During disease progression and after irradiation, the language-related brain network was extended or completely transferred to the nondominant (right) hemisphere. In addition, after reoperation and 1 year after irradiation, language areas were primarily found in the language dominant (left) hemisphere. Our results suggest a high level of adaptability of the language-related cortical network of the bilateral hemispheres in this low-grade glioma patient. 展开更多
关键词 functional magnetic resonance imaging low-grade glioma cortical changes language-related brain network
下载PDF
CT-MRI同体位图像融合在高级别脑胶质瘤放射治疗靶区勾画中应用 被引量:1
9
作者 金龙 杨振 +2 位作者 张鑫 刘晓斌 缪星宇 《生物医学工程与临床》 CAS 2024年第1期35-41,共7页
目的探讨同体位MRI图像(MRIsim)与CT模拟定位图像融合在高级别脑胶质瘤放射治疗靶区勾画中的临床应用价值。方法选择20例脑胶质瘤术后放射治疗患者,其中男性13例,女性7例;年龄39~69岁,平均年龄45.5岁;全部为单发病变;均已行全切或不全... 目的探讨同体位MRI图像(MRIsim)与CT模拟定位图像融合在高级别脑胶质瘤放射治疗靶区勾画中的临床应用价值。方法选择20例脑胶质瘤术后放射治疗患者,其中男性13例,女性7例;年龄39~69岁,平均年龄45.5岁;全部为单发病变;均已行全切或不全切手术,全部经病理组织诊断证实;世界卫生组织(WHO)分级Ⅲ级6例,Ⅳ级14例。将每例患者的同体位MRIsim、常规MRI影像(MRIconv)分别与CT模拟定位图像融合。运用Dice相似指数(DSC)和豪斯多夫距离(HD)算法来评价配准的精确度。在CT与MRIsim融合图像(Fusion-CT MRIsim)、CT与MRIconv融合图像(Fusion-CT MRIconv)上分别勾画危及器官(OAR)及靶区[大体肿瘤靶区(GTV)、临床肿瘤靶区(CTV)]。评估两种融合图像(即Fusion-CT MRIsim组和Fusion-CT MRIconv组)OAR勾画体积、GTV、CTV及剂量学差异。结果融合精确度评估:除全脑外,Fusion-CT MRIsim组其余OAR DSC均高于Fusion-CT MRIconv组(P<0.05);Fusion-CT MRIsim组OAR HD小于Fusion-CT MRIconv组(P<0.05)。OAR勾画体积比较:Fusion-CT MRIsim组OAR勾画体积与Fusion-CT MRIconv比较,差异无统计学意义(P>0.05)。靶区:Fusion-CT MRIsim组GTV、CTV小于Fusion-CT MRIconv组[(118.2±8.0)cm^(3)vs(125.3±8.1)cm^(3)、(234.3±12.8)cm^(3)vs(256.0±13.4)cm^(3)],差异有显著统计学意义(均P=0.000)。剂量学比较:Fusion-CT MRIsim组D_(max)-PTV、D_(mean)-PTV与Fusion-CT MRIconv组[(6432.9±23.0)cGy vs(6430.4±25.2)cGy、(6159.0±13.7)cGy vs(6166.2±17.3)cGy]比较,差异无统计学意义(P>0.05)。结论CT-MRI同体位融合图像配准精确度高,可降低全脑平均剂量(D_(mean))及缩小GTV及CTV,是高级别脑胶质瘤术后精确放射治疗值得广泛应用的临床方法。 展开更多
关键词 CT-MRI同体位融合 高级别胶质瘤 放射治疗靶区 靶区勾画
下载PDF
H3和IDH野生型弥漫性儿童型高级别胶质瘤6例临床病理分析
10
作者 王瑞芬 管雯斌 +3 位作者 严敏骅 琚璐 韩蕙如 王立峰 《临床与实验病理学杂志》 CAS 北大核心 2024年第5期484-489,共6页
目的探讨中枢神经系统H3和IDH野生型弥漫性儿童型高级别胶质瘤的临床病理学及分子特征。方法收集上海交通大学医学院附属新华医院病理科诊断的6例H3和IDH野生型弥漫性儿童型高级别胶质瘤的临床病理资料,采用免疫组化(全自动免疫组化染色... 目的探讨中枢神经系统H3和IDH野生型弥漫性儿童型高级别胶质瘤的临床病理学及分子特征。方法收集上海交通大学医学院附属新华医院病理科诊断的6例H3和IDH野生型弥漫性儿童型高级别胶质瘤的临床病理资料,采用免疫组化(全自动免疫组化染色仪)检测GFAP、Olig2、Syn、NeuN、IDH1、H3K27M等蛋白的表达,FISH法检测EGFR、MYCN基因扩增,Sanger测序检测IDH、H3F3A、TERT基因突变,并复习相关文献。结果本组6例患者年龄范围5~11岁,中位年龄7.5岁。其中男性2例,女性4例,男女比1∶2。临床症状表现为肢体乏力、偏瘫、呕吐、抽搐、视物模糊等。肿瘤发生部位:5例位于幕上,1例位于幕下脑干和小脑。组织学形态:3例表现为高级别胶质瘤形态学特征,其中2例伴有瘤巨细胞;2例表现为胚胎性肿瘤样特征,1例同时具有高级别胶质瘤及胚胎性肿瘤样形态学特点。5例伴有微血管增生和(或)坏死;1例间质黏液变/微囊形成。免疫表型:肿瘤细胞GFAP(6/6)和Olig2(6/6)部分或局灶阳性,Syn(3/6)和NeuN(1/6)局灶或散在阳性,IDH1、H3K27M、H3G34V和H3G34R均阴性,ATRX、H3K27me3、INI1、BRG1均弥漫阳性(6/6)。p53阳性5%~95%不等,Ki67增殖指数40%~90%。分子检测示6例均为IDH1/2和H3F3A野生型;2例MYCN扩增;2例EGFR扩增伴多倍体;1例同时伴有EGFR扩增和MYCN扩增;1例PDGFRA扩增。治疗及随访情况,术后放疗和(或)替莫唑胺化疗;3例于术后1~5个月死亡;2例存活,随访截至2024年1月,分别随访4个月和7个月;1例失访。结论H3和IDH野生型弥漫性儿童型高级别胶质瘤是一种高度恶性肿瘤,组织学表现为胶质母细胞瘤样或胚胎性肿瘤样特征,根据分子遗传学特征分为RTK1、RTK2、MYCN三种分子亚型,其中MYCN亚型预后最差。诊断时应注意与其他儿童型或成人型高级别胶质瘤及胚胎性肿瘤鉴别。 展开更多
关键词 弥漫性儿童型高级别胶质瘤 H3野生型 IDH野生型 鉴别诊断
下载PDF
磁共振增强扫描无强化的不同级别脑胶质瘤临床特征的对比分析
11
作者 曾令成 厉华 +3 位作者 陈如东 杨洪宽 陈坚 于加省 《中华神经外科杂志》 CSCD 北大核心 2024年第11期1125-1130,共6页
目的通过与磁共振增强扫描无强化的低级别脑胶质瘤患者进行对比,探讨磁共振增强扫描无强化的高级别脑胶质瘤的临床特征。方法回顾性分析2021年1月至2023年12月华中科技大学同济医学院附属同济医院神经外科收治的磁共振增强扫描无强化、... 目的通过与磁共振增强扫描无强化的低级别脑胶质瘤患者进行对比,探讨磁共振增强扫描无强化的高级别脑胶质瘤的临床特征。方法回顾性分析2021年1月至2023年12月华中科技大学同济医学院附属同济医院神经外科收治的磁共振增强扫描无强化、接受手术治疗且病理学诊断明确的成人(年龄≥18岁)脑胶质瘤患者的临床资料。通过单因素分析对比高级别组[世界卫生组织(WHO)3、4级]与低级别组(WHO2级)的临床特征,并将其中差异具有统计学意义(P<0.05)的因素纳人多因素logistic回归模型分析,寻找与高级别相关联的特征。结果共纳人126例患者,其中高级别组46例(36.5%),包括38例WHO3级和8例WHO4级患者;低级别组80例(63.5%)。单因素分析结果表明,两组患者的年龄、肿瘤生长速率、相对表观弥散系数、胆碱/肌酸及胆碱/N-乙酰天冬氨酸值、危险程度的差异均有统计学意义(均P<0.05),而性别、有无癫痫发作、肿瘤的最大径或部位、有无瘤周水肿、T2-液体衰减反转恢复序列错配征、肿瘤病理学类型的差异均无统计学意义(均P>0.05)。多因素logistic回归模型分析显示,患者的年龄>40岁(0R=3.55,95%CI:1.30~11.48)、肿瘤生长速率>8mm/年(OR=17.30,95%CI:7.89~41.94)、较低的相对表观弥散系数(OR=0.77,95%CI:0.56~0.97)、较高的胆碱/肌酸比值(OR=1.14,95%CI:1.08~1.20)和胆碱/N-乙酰天冬氨酸比值(OR=3.73,95%CI:1.50~9.35)与肿瘤呈高级别有关(均P<0.05)。结论对于年龄>40岁和(或)肿瘤生长速率>8mm/年的磁共振增强无强化的脑胶质瘤患者,术前需高度警惕其病变为高级别的可能;进一步配合功能磁共振弥散加权成像和(或)磁共振波谱检查有助于术前对肿瘤级别的判断。 展开更多
关键词 神经胶质瘤 疾病特征 磁共振成像 无强化 高级别
原文传递
替莫唑胺联合伽玛刀立体定向放射治疗高级别脑胶质瘤预后及术后残留复发影响因素分析
12
作者 付琳 兰艳 《中国药业》 CAS 2024年第20期112-115,共4页
目的探讨替莫唑胺联合伽玛刀立体定向放射治疗高级别脑胶质瘤术后残留的预后,并分析其影响因素。方法选取医院2021年1月至2023年1月收治的高级别脑胶质瘤术后残留患者117例,根据治疗方案的不同分为对照组(54例)和观察组(63例)。两组均... 目的探讨替莫唑胺联合伽玛刀立体定向放射治疗高级别脑胶质瘤术后残留的预后,并分析其影响因素。方法选取医院2021年1月至2023年1月收治的高级别脑胶质瘤术后残留患者117例,根据治疗方案的不同分为对照组(54例)和观察组(63例)。两组均行伽玛刀立体定向放射治疗,然后行脱水治疗3~5 d;观察组患者加服替莫唑胺胶囊,治疗2周期。比较两组临床疗效、不良反应发生情况及术后残留复发情况。采用单因素分析和二元Logistic回归分析识别联合治疗患者术后残留复发的独立危险因素。结果观察组总有效率为73.02%,显著高于对照组的48.15%(P<0.05);观察组不良反应发生率与对照组相当(55.56%比64.81%,P>0.05);观察组术后残留复发率为22.22%,显著低于对照组的40.74%(P<0.05)。患者年龄(≥60岁)、肿瘤直径(≥5 cm)及次全切治疗均为影响术后残留复发的独立危险因素(P<0.05)。结论替莫唑胺联合伽玛刀立体定向放射治疗高级别脑胶质瘤,可进一步提升疗效,降低术后残留复发风险。患者年龄(≥60岁)、肿瘤直径(≥5 cm)、次全切治疗为患者术后残留复发的独立危险因素。 展开更多
关键词 替莫唑胺 伽玛刀立体定向放射 高级别脑胶质瘤 术后残留复发 影响因素
下载PDF
复发高级别脑胶质瘤患者伽玛刀放疗预后危险因素及风险预测模型构建
13
作者 秦德华 卜亚静 +2 位作者 时昌立 安全 梁武龙 《河南医学研究》 CAS 2024年第8期1388-1392,共5页
目的分析复发高级别脑胶质瘤患者伽玛刀放疗预后的危险因素,并构建风险预测模型。方法回顾性收集2019年1月至2022年1月于医院接受伽玛刀放疗的85例复发高级别脑胶质瘤患者临床资料,依据随访1 a期间预后情况将资料分为病死组(n=40)与存活... 目的分析复发高级别脑胶质瘤患者伽玛刀放疗预后的危险因素,并构建风险预测模型。方法回顾性收集2019年1月至2022年1月于医院接受伽玛刀放疗的85例复发高级别脑胶质瘤患者临床资料,依据随访1 a期间预后情况将资料分为病死组(n=40)与存活组(n=45)。采用Cox回归分析影响复发高级别脑胶质瘤患者伽玛刀放疗预后的因素,根据回归分析结果构建风险预测模型,利用R软件构建列线图,并绘制受试者工作特征曲线评估风险模型的预测效能。结果病死组年龄、最大肿瘤直径大于存活组,而靶区周边剂量、放疗前Karnofsky功能状态(KPS)评分低于存活组,差异有统计学意义(P<0.05);经Cox回归分析显示,年龄、最大肿瘤直径为复发高级别脑胶质瘤患者伽玛刀放疗后病死的危险因素(HR>1,P<0.05),而靶区周边剂量、放疗前KPS评分为复发高级别脑胶质瘤患者伽玛刀放疗后病死的保护因素(HR<1,P<0.05);绘制列线图构建复发高级别脑胶质瘤患者伽玛刀放疗预后病死风险预测模型,验证模型区分度显示一致性指数(C-index)值=0.876,具有良好的区分度;绘制标准曲线显示,校准曲线与Y-X直线相近,模型准确度良好。结论年龄、靶区周边剂量、最大肿瘤直径、KPS评分为复发高级别脑胶质瘤患者伽玛刀放疗预后的影响因素,基于以上因素构建的风险模型对于复发高级别脑胶质瘤患者伽玛刀放疗预后的预测价值较高,具有良好的临床应用价值。 展开更多
关键词 高级别脑胶质瘤 复发 伽玛刀放疗 预后 影响因素 风险预测模型
下载PDF
动态增强MR联合酰胺质子转移成像检测对脑肿瘤诊断及分级的临床价值
14
作者 许跃根 郑顺勇 《医疗装备》 2024年第19期1-4,9,共5页
目的探讨动态增强MR(DCE-MR)联合酰胺质子转移成像(APT)检测对脑肿瘤诊断及分级的临床效能。方法选取2020年6月至2023年6月医院收治的40例脑胶质瘤患者为试验组,以同期收治的24例颅内良性肿瘤患者为对照组。对所有患者均行DCE-MR和APT扫... 目的探讨动态增强MR(DCE-MR)联合酰胺质子转移成像(APT)检测对脑肿瘤诊断及分级的临床效能。方法选取2020年6月至2023年6月医院收治的40例脑胶质瘤患者为试验组,以同期收治的24例颅内良性肿瘤患者为对照组。对所有患者均行DCE-MR和APT扫描,比较两组影像学表现及肿瘤实质区的平均APT(mAPT)、平均容积转运常数(mKtrans)、血管外细胞外间隙容积比(Ve)图,分析各指标对脑胶质瘤诊断及分级的临床效能。结果脑胶质瘤DCE-MR图像显示,低级别脑胶质瘤影像学表现为长T1、T2,肿瘤大小、位置等分布较均衡,坏死部位较少见;15例低级别脑胶质瘤患者中3例出现轻度增强改变,12例未出现增强改变;高级别脑胶质瘤多以长T1、长T2为主的混杂信号为主,信号分布不均;25例高级别脑胶质瘤患者中22例出现显著增强改变,3例未出现任何增强改变。脑胶质瘤APT图像显示,脑白质信号正常以绿色为主;高级别脑胶质瘤表现为红、黄色高信号为主的异常信号,局部病灶密度增加,血液供应丰富在APT图像上也呈现高信号;高级别脑胶质瘤患者中3例无强化病例的胶质瘤核心区域在APT图像上呈现高信号;低级别脑胶质瘤在APT图像上为淡黄色-绿色的低信号改变,肿瘤中心区域没有或仅有轻微APT增强改变。试验组m APT、mK^(trans)、V_(e)水平高于对照组,差异有统计学意义(P<0.05);m APT、mK^(trans)、V_(e)及联合检测诊断脑胶质瘤的受试者工作特征(ROC)曲线下面积(AUC)分别为0.769、0.820、0.670、0.872,差异有统计学意义(P<0.05)。40例脑胶质瘤患者经病理确诊分为低级别组(15例)与高级别组(25例),低级别组的mAPT、mK^(trans)、V_(e)水平低于高级别组,差异有统计学意义(P<0.05);mAPT、mK^(trans)、V_(e)及联合检测诊断脑胶质瘤分级的AUC分别为0.877、0.864、0.851、0.941,差异有统计学意义(P<0.05)。结论DCE-MR联合APT检测可用于胶质瘤的临床诊断和分级,应用价值较好。 展开更多
关键词 动态增强MR 酰胺质子转移成像 脑胶质瘤 分级 临床效能
下载PDF
基于磁共振影像组学和语义特征对高级别胶质瘤和转移瘤的鉴别研究
15
作者 徐子超 张娅 +5 位作者 柳青 史朝霞 王静 卫宏洋 彭兴珍 宗会迁 《磁共振成像》 CAS CSCD 北大核心 2024年第8期103-109,123,共8页
目的本研究旨在结合传统MRI序列及增强检查,提取多模态高通量影像组学特征并联合语义特征,使用不同的机器学习分类器构建不同的模型并绘制列线图来鉴别高级别胶质瘤(high-grade glioma,HGG)和单发性脑转移瘤(solitary brain metastasis,... 目的本研究旨在结合传统MRI序列及增强检查,提取多模态高通量影像组学特征并联合语义特征,使用不同的机器学习分类器构建不同的模型并绘制列线图来鉴别高级别胶质瘤(high-grade glioma,HGG)和单发性脑转移瘤(solitary brain metastasis,SBM)。材料与方法本研究对101名患者的多参数MR图像进行了回顾性分析,由两位资深医师标定肿瘤感兴趣区,然后对每个序列分别提取影像组学特征后进行组合,共提取428组影像组学特征。为消除人为标定差异,进行组内相关系数一致性检验,并运用最大相关最小冗余算法选取最具相关性的特征,然后进一步通过最小绝对收缩和选择算子算法筛除冗余特征。本研究采用支持向量机、逻辑回归、随机森林及K近邻四种算法建立分类模型。结合放射科医生评估的七项语义特征,通过卡方检验和多因素分析去除差异无统计学意义的语义特征。然后结合组学特征建立综合模型并绘制列线图。最终,评价各模型的诊断能力,以确定最优分类器。结果HGG及SBM患者建立的影像组学模型中LR的受试者工作特征曲线下面积(area under the curve,AUC)值最高,训练集与测试集分别为0.90和0.90。语义特征建立的模型中随机森林模型性能最好,训练集和测试集AUC分别为0.82和0.87。语义特征联合影像组学评分后采用逻辑回归建立的模型性能最好,训练集和测试集AUC分别为0.91和0.92。结论本研究使用影像组学机器学习分类器并联合其他图像语义特征绘制列线图对HGG及SBM进行鉴别,这是一种非侵入性方法,具有较好的准确性,为临床决策和实践提供了较大的帮助。 展开更多
关键词 高级别胶质瘤 单发性脑转移瘤 磁共振成像 影像组学 机器学习 语义特征 列线图
下载PDF
出血性高级别脑动静脉畸形血管内治疗的临床疗效分析 被引量:1
16
作者 邵哲 陈健龙 +3 位作者 郭大闯 冯基高 吕久一 彭浩 《海南医学》 CAS 2024年第14期2012-2016,共5页
目的观察出血性高级别脑动静脉畸形(BAVM)血管内治疗的临床疗效。方法回顾性分析2017年1月至2023年1月海南省人民医院采用血管内治疗的37例高级别脑动静脉畸形患者的临床资料。所有患者术前均行CT血管造影(CTA)、数字减影血管造影(DSA)... 目的观察出血性高级别脑动静脉畸形(BAVM)血管内治疗的临床疗效。方法回顾性分析2017年1月至2023年1月海南省人民医院采用血管内治疗的37例高级别脑动静脉畸形患者的临床资料。所有患者术前均行CT血管造影(CTA)、数字减影血管造影(DSA)分析脑动静脉畸形血管的构筑。血管内治疗采用动脉入路、静脉入路、分次治疗、高压锅等技术,未完全栓塞患者术后行放射治疗。术后定期随访3个月,行CT、CTA或DSA复查,并进行格拉斯哥预后评分(GOS)以评估神经功能的恢复情况。结果按Spetzler-Martin分级,37例高级别脑动静脉畸形患者中Ⅳ级25例和Ⅴ级12例;单支动脉供血10例,多支动脉供血27例,畸形团单次栓塞6例,分次栓塞31例。治愈性栓塞29.7%(11/37),大部分栓塞54.1%(20/37),部分栓塞16.2%(6/37);术后随访3个月,按GOS评分评价预后,其中恢复良好56.8%(21/37),轻度残疾21.6%(8/37),重度残疾10.8%(4/37),植物生存8.1%(3/37),死亡2.7%(1/37)。结论血管内介入技术治疗出血性高级别脑动静脉畸形临床疗效可靠。 展开更多
关键词 脑出血 高级别颅内动静脉畸形 血管内治疗 栓塞 疗效
下载PDF
基于序列缺失的MRI多序列特征填补与融合互助模型:鉴别高低级别胶质瘤
17
作者 吴垂杏 钟伟雄 +5 位作者 谢金城 杨蕊梦 吴元魁 许乙凯 王琳婧 甄鑫 《南方医科大学学报》 CAS CSCD 北大核心 2024年第8期1561-1570,共10页
目的探讨基于序列缺失的MRI多序列特征填补与融合互助模型应用于高级别胶质瘤(HGG)与低级别胶质瘤(LGG)鉴别的性能表现。方法回顾性收集305例胶质瘤患者(189例HGG,116例LGG)的MRI图像,分别勾画出T1加权成像(T1WI)、T2加权成像(T2WI)、T... 目的探讨基于序列缺失的MRI多序列特征填补与融合互助模型应用于高级别胶质瘤(HGG)与低级别胶质瘤(LGG)鉴别的性能表现。方法回顾性收集305例胶质瘤患者(189例HGG,116例LGG)的MRI图像,分别勾画出T1加权成像(T1WI)、T2加权成像(T2WI)、T2液体翻转恢复衰减(T2_FLAIR)和T1WI增强图像(CE_T1WI)的感兴趣区(ROI),提取出4个ROI的影像组学特征。利用本研究提出的基于序列缺失的MRI多序列特征填补与融合互助模型对含有缺失数据的特征矩阵进行填补与融合双向学习得到互助模型。采用五折交叉验证方法和准确率(ACC)、平衡准确率(BAcc)、ROC曲线下的面积(AUC)、特异性和灵敏度评价该模型的鉴别能力。所提模型与其他非完整多模态分类模型在鉴别HGG与LGG上进行定量比较,对本文提出的特征填补与融合方法学习得到的潜在特征进行类可分性实验,观察样本在二维平面的分类效果,采用收敛性实验验证该模型的可行性。结果模型序列缺失率为10%时,其在鉴别HGG与LGG的ACC、BAcc、AUC、特异性、灵敏度分别为:0.777、0.768、0.826、0.754和0.780,融合的潜在特征在类可分性实验中有优秀表现,该算法可迭代至收敛。缺失率为30%、50%时,分类性能也优于其他方法。结论基于序列缺失的MRI多序列特征填补与融合互助模型在HGG和LGG的分类任务中具有优异的性能表现。与其他非完整多模态分类模型相比,该模型在鉴别HGG和LGG的分类性能更优,适用于非完整模态的多模态数据的处理。 展开更多
关键词 序列缺失 特征填补 表征学习 高级别胶质瘤 低级别胶质瘤
下载PDF
胶质瘤化疗中国专家共识
18
作者 中国抗癌协会神经肿瘤专业委员会 陈忠平 +13 位作者 初曙光 郭琤琤 赫振炎 李刚 平轶芳 邱献新 赛克 苏君 汪洋 温源 杨光 杨群英 张俊平 张烨 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2024年第8期449-462,共14页
胶质瘤是最常见的颅内原发性恶性肿瘤。目前,治疗以手术切除为主,辅以放疗和化疗。临床实践证明,胶质瘤化疗极具意义,已被广泛应用于新诊断的胶质瘤术后辅助治疗和复发胶质瘤的挽救治疗。为进一步规范胶质瘤的化疗过程,提高治疗效果,中... 胶质瘤是最常见的颅内原发性恶性肿瘤。目前,治疗以手术切除为主,辅以放疗和化疗。临床实践证明,胶质瘤化疗极具意义,已被广泛应用于新诊断的胶质瘤术后辅助治疗和复发胶质瘤的挽救治疗。为进一步规范胶质瘤的化疗过程,提高治疗效果,中国抗癌协会神经肿瘤专业委员会组织相关专家,编写了《胶质瘤化疗中国专家共识》(以下简称《共识》),为广大同仁提供临床实际操作参考。《共识》从胶质瘤化疗相关的病理知识、化疗过程中患者管理、影像学评价、不同级别胶质瘤、新诊断或复发患者、如何结合其他治疗策略等角度对化疗方案进行了介绍。 展开更多
关键词 胶质瘤 高级别胶质瘤 化疗策略 化疗方案 专家共识
下载PDF
替尼泊苷动脉化疗联合贝伐珠单抗在复发高级别脑胶质瘤的临床回顾性研究
19
作者 胡丹 裴玉春 +1 位作者 张希 周昌龙 《重庆医科大学学报》 CAS CSCD 北大核心 2024年第3期335-339,共5页
目的:探索替尼泊苷超选动脉化疗联合贝伐珠单抗在复发高级别脑胶质瘤治疗的临床疗效和安全性。方法:79例复发高级别脑胶质瘤患者按治疗方法的不同,分为试验组37例(替尼泊苷动脉化疗联合贝伐珠单抗治疗)和对照组42例(贝伐珠单抗单药治疗)... 目的:探索替尼泊苷超选动脉化疗联合贝伐珠单抗在复发高级别脑胶质瘤治疗的临床疗效和安全性。方法:79例复发高级别脑胶质瘤患者按治疗方法的不同,分为试验组37例(替尼泊苷动脉化疗联合贝伐珠单抗治疗)和对照组42例(贝伐珠单抗单药治疗),比较两组患者脑胶质瘤维持治疗后的客观缓解率、疾病控制率及不良反应率,评估O~6-甲基鸟嘌呤-DNA甲基转移酶基因启动子甲基化状态对两组患者疾病控制率的影响。结果:试验组和对照组的客观缓解率分别为43.2%和21.4%(P=0.038),疾病控制率分别为78.4%和54.8%(P=0.027)。试验组在轻度消化道反应(P=0.044)、头痛(P=0.044)及白细胞减少(P=0.026)的不良反应发生率高于对照组。试验组年龄小于60岁人群的疾病控制率较对照组明显增加(P<0.05)。结论:在高级别脑胶质瘤维持治疗中,替尼泊苷超选动脉化疗联合贝伐珠单抗的疗效优于贝伐珠单抗单药治疗,值得临床进一步推广。 展开更多
关键词 替尼泊苷 贝伐珠单抗 复发高级别脑胶质瘤 治疗 疗效
下载PDF
基于距匹配及判别表征学习的多模态特征融合分类模型研究:高级别胶质瘤与单发性脑转移瘤的鉴别诊断
20
作者 张振阳 谢金城 +3 位作者 钟伟雄 梁芳蓉 杨蕊梦 甄鑫 《南方医科大学学报》 CAS CSCD 北大核心 2024年第1期138-145,共8页
目的探索基于距匹配及判别表征学习的多模态特征融合分类模型在鉴别高级别胶质瘤(HGG)与单发性脑转移(SBM)中的鉴别能力和应用价值。方法收集了121例患者(61例HGG和60例SBM)的多参数磁共振成像(MRI)扫描图像,在T1W1、T2W1、T2加权液体... 目的探索基于距匹配及判别表征学习的多模态特征融合分类模型在鉴别高级别胶质瘤(HGG)与单发性脑转移(SBM)中的鉴别能力和应用价值。方法收集了121例患者(61例HGG和60例SBM)的多参数磁共振成像(MRI)扫描图像,在T1W1、T2W1、T2加权液体衰减反转恢复(T2_FLAIR)和T1WI增强图像(CE_T1WI)4种常规轴位MRI图像上勾画目标感兴趣区域(ROI),并使用开源影像组学工具Pyradiomics从4个MRI序列分别提取影像组学特征。使用本研究提出的基于距匹配及判别表征学习的多模态特征融合分类模型对4个MRI序列的影像组学特征进行融合并得到分类模型。采用五折交叉验证方法和特异性(SPE)、灵敏度(SEN)、准确率(ACC)、ROC曲线下面积(AUC)评价该分类模型的鉴别性能。将本研究所提模型与其他特征融合分类模型对于HGG与SBM的鉴别能力进行定量比较,同时对本研究提出特征融合方法得到的融合特征进行样本散点可视化实验,验证本研究所提出的多模态特征融合分类模型的可行性和有效性。结果五折交叉验证结果显示本研究所提出的基于距匹配及判别表征学习的多模态特征融合分类模型在鉴别高级别胶质瘤与单发性脑转移瘤中的SPE、SEN、ACC、AUC分别为:0.871、0.817、0.843、0.930,且特征融合方法在可视化实验中具有优秀的表现。结论基于距匹配及判别表征学习的多模态特征融合分类模型在鉴别高级别胶质瘤与单发性脑转移瘤中的应用具有优秀的鉴别能力和较高的应用价值。同时,与其他特征融合分类模型相比,本研究提出的分类模型在HGG与SBM的鉴别分类任务中具有较大的优势。 展开更多
关键词 特征融合 共享表征学习 判别分析 高级别胶质瘤 单发性脑转移瘤
下载PDF
上一页 1 2 20 下一页 到第
使用帮助 返回顶部